Last reviewed · How we verify
NCT06232707: ALUMMINATE
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3 trial testing Alnuctamab in Multiple Myeloma. Withdrawn.
16 November 2025
Quick facts
| Lead sponsor | Celgene |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 3 May 2024 |
| Primary completion | 16 November 2025 |
| Estimated completion | 21 September 2030 |
| Sites | 170 locations across Italy, Japan, Ireland, South Korea, Belgium, Sweden, Czechia, Portugal |
Drugs / interventions tested
- Alnuctamab
- Pomalidomide — full drug profile →
- Daratumumab (daratumumab) — full drug profile →
- Elotuzumab (elotuzumab) — full drug profile →
- Carfilzomib (carfilzomib) — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Celgene — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.
Radtke KK, Bender BC, Li Z, Turner DC, et al · · 2025 · cited 30× · PMID 39556515 · DOI 10.1158/1078-0432.ccr-24-2247 -
Structure and function of therapeutic antibodies approved by the US FDA in 2023.
Strohl WR. · · 2024 · cited 25× · PMID 38617189 · DOI 10.1093/abt/tbae007 -
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Parrondo RD, Ailawadhi S, Cerchione C. · · 2024 · cited 10× · PMID 38660139 · DOI 10.3389/fonc.2024.1394048 -
Bispecific antibodies: unleashing a new era in oncology treatment.
Shui L, Wu D, Yang K, Sun C, et al · · 2025 · cited 6× · PMID 40760704 · DOI 10.1186/s12943-025-02390-y -
Current Treatment Strategies for Multiple Myeloma at First Relapse.
Mavrothalassitis E, Triantafyllakis K, Malandrakis P, Gavriatopoulou M, et al · · 2025 · cited 2× · PMID 40095642 · DOI 10.3390/jcm14051655 -
EHA2024 Hybrid Congress
· 2024
Verify or expand the search:
- PubMed search for NCT06232707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alnuctamab
Trials testing the same drug.
- NCT06163898 — A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple · Phase 1 · active not recruiting
- NCT06121843 — A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combi · Phase 1 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Celgene trials
Trials by the same sponsor.
- NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
- NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
- NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06232707 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Celgene
- Last refreshed: 31 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing